JACC Specialty Journals

by American College of Cardiology

In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including…

Apple Podcasts

Spotify

Episodes

Plasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: AsiaPlasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: Asia

Nov 3

Commentary by Dr. Athanasios Sakalidis.

Nov 3

Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: AsiaReal-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: Asia

Nov 3

Commentary by Dr. Heerajnarain Bulluck.

Nov 3

Multimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: AsiaMultimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: Asia

Nov 3

Commentary by Dr. Milan Prsa.

Nov 3

Osteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: AsiaOsteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: Asia

Nov 3

Commentary by Dr. Yuhi Fujimoto.

Nov 3

Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: AsiaEpidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: Asia

Nov 3

Commentary by Dr. Yoshihiro Miyamoto.

Nov 3

Advances in a Capsule: October 2026 | JACC: AdvancesAdvances in a Capsule: October 2026 | JACC: Advances

Oct 29

Audio Summary of three articles from the October 2026 issue of JACC: Advances.

Oct 29

XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: AsiaXGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia

Oct 20

Commentary by Dr. Yoriyasu Suzuki.

Oct 20

Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: AsiaDesign and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia

Oct 20

Commentary by Dr. Junjie Yang.

Oct 20

Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: AsiaPrediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia

Oct 20

Commentary by Dr. Qinkai Yu.

Oct 20

October 2026 Summary | JACC: CardioOncologyOctober 2026 Summary | JACC: CardioOncology

Oct 20

Editor-in-Chief Dr. Bonnie Ky introduces the October 2026 issue of JACC: CardioOncology, featuring Part 1 of a special focus on immunology and cardio-oncology. This issue brings together state-of-the-art reviews, primers, original research, and clinical cases examining the immune system's central role in cancer and…

Oct 20

Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncologyFibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology

Oct 20

Dr. Caitlin O'Meara discusses a JACC: CardioOncology study showing that doxorubicin reprograms CD8+ T cells into matrix-remodeling T cells (mxT-cells) that produce lysyl oxidase (LOX) and stiffen the cardiac extracellular matrix through HIF1α-P53-TGFβ signaling. She explains how this new immune mechanism of…

Oct 20

High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncologyHigh-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology

Oct 20

Dr. David Austin discusses a JACC: CardioOncology study showing that high-sensitivity cardiac troponin T was elevated in 37.9% of patients starting immune checkpoint inhibitor (ICI) therapy, compared with only 1.8% for high-sensitivity troponin I, a discordance linked to older age, male sex, and kidney dysfunction. He…

Oct 20